Drugs / oyster mushroom
oyster mushroom
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00069524 | Jun 2004 → May 2006 | HIV infectious disease, hyperlipidemia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oyster mushroom | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069524 ↗ |
| Known as | oyster mushrooms | “The primary goal of this study is to evaluate the short-term safety and potential efficacy of oyster mushrooms (Pleurotus ostreatus) for treatment of hyperlipidemia in...” NCT00069524 ↗ |
| Known as | Pleurotus ostreatus | “The oyster mushroom, Pleurotus ostreatus, has been shown in animal models to decrease lipid levels” PMID 21831304 ↗ Aug 2011 |
| Route | Oral | “to be administered orally for the 8 week trial period.” PMID 21831304 ↗ Aug 2011 |